MedPath

Xoma (US) LLC

πŸ‡ΊπŸ‡ΈUnited States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

41

Active:16
Completed:16

Trial Phases

4 Phases

Phase 1:10
Phase 2:12
Phase 3:7
+1 more phases

Drug Approvals

1

FDA:1

Drug Approvals

Aceon

Approval Date
Mar 11, 2013
FDA

Clinical Trials

Distribution across different clinical trial phases (30 trials with phase data)β€’ Click on a phase to view related trials

Phase 2
12 (40.0%)
Phase 1
10 (33.3%)
Phase 3
7 (23.3%)
Not Applicable
1 (3.3%)

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

Phase 2
Completed
Conditions
Hypoglycemia
Interventions
Drug: XOMA 358 single dose level A
Drug: XOMA 358 multiple dose level 1
Drug: XOMA 358 single dose level B
Drug: XOMA 358 single dose level C
First Posted Date
2016-05-13
Last Posted Date
2021-05-21
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
20
Registration Number
NCT02772718

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

Phase 2
Completed
Conditions
Congenital Hyperinsulinism
Interventions
Drug: Cohort 1
Drug: Cohort 2
Drug: Cohort 3
Drug: Cohort 4
First Posted Date
2015-11-13
Last Posted Date
2017-02-06
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
10
Registration Number
NCT02604485

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Phase 3
Terminated
Conditions
Pyoderma Gangrenosum
Interventions
First Posted Date
2014-12-29
Last Posted Date
2016-04-27
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
9
Registration Number
NCT02326740

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Phase 3
Terminated
Conditions
Pyoderma Gangrenosum
Interventions
First Posted Date
2014-12-17
Last Posted Date
2016-04-27
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
15
Registration Number
NCT02318914

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Phase 3
Terminated
Conditions
Pyoderma Gangrenosum
Interventions
First Posted Date
2014-12-11
Last Posted Date
2016-04-27
Lead Sponsor
XOMA (US) LLC
Target Recruit Count
16
Registration Number
NCT02315417
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.